Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Rating of "Moderate Buy" from Analysts
Thirteen research firms have given Syndax Pharmaceuticals (NASDAQ:SNDX) an average recommendation of "Moderate Buy," with an average 12-month price target of $41.91. Despite missing Q2 earnings and revenue estimates and insider share sales, institutional investors like BlackRock and Vanguard have increased their stakes. The company, focused on developing cancer therapies, maintains a positive outlook from analysts.
GSA Capital Partners LLP Purchases New Position in Syndax Pharmaceuticals, Inc. $SNDX
GSA Capital Partners LLP has acquired a new position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX), purchasing 62,775 shares valued at approximately $1.37 million during the second quarter. This move comes as several other institutional investors also increased their holdings in the company. Despite missing revenue and EPS estimates in its latest earnings report, analysts maintain a "Moderate Buy" consensus rating for Syndax Pharmaceuticals, with an average price target of $41.91.
The Technical Signals Behind (SNDX) That Institutions Follow
Stock Traders Daily provides a technical analysis of Syndax Pharmaceuticals Inc. (NASDAQ: SNDX), highlighting a mid-channel oscillation pattern with positive near-term sentiment within a long-term strength context. The analysis details three institutional trading strategies (Position Trading, Momentum Breakout, and Risk Hedging) and offers multi-timeframe signal analysis with specific support and resistance levels. The report also notes an exceptional 58.7:1 risk-reward setup.
SNDX Maintained by JP Morgan -- Price Target Lowered to $40.00
JP Morgan has maintained an "Overweight" rating on Syndax Pharmaceuticals (SNDX) but lowered its price target from $44.00 to $40.00. The company, with a market cap of $1.81 billion, faces challenges indicated by its GF Score™ of 22/100 and a high price-to-sales ratio of 77.2x. Insider activity shows net selling, suggesting caution for investors despite the analyst's "Overweight" rating.
Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $40.00 Price Target at JPMorgan Chase & Co.
JPMorgan Chase & Co. has lowered its price target for Syndax Pharmaceuticals (NASDAQ:SNDX) from $44.00 to $40.00, while maintaining an "overweight" rating. Despite the reduced target, the average analyst rating for SNDX remains "Moderate Buy" with a consensus price target of $41.91, suggesting significant upside potential. The company recently missed earnings estimates, reporting an adjusted loss of $0.55 per share and revenue of $72.79 million against expectations.
Syndax Pharmaceuticals (SNDX) Stock Looks Stretched As Its 63% Run Continues
Syndax Pharmaceuticals (SNDX) has seen a 63.5% gain over the past year, but its current share price of US$20.40 appears stretched based on valuation metrics. Despite pipeline progress, the stock's P/S ratio of 7.2x is above its tailored fair P/S of 3.4x, suggesting it may be overvalued relative to its fundamentals. The company's future performance hinges on its oncology pipeline's ability to translate into revenue that justifies the current investor optimism.
Hennion & Walsh Asset Management Inc. Increases Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX
Hennion & Walsh Asset Management Inc. significantly increased its stake in Syndax Pharmaceuticals, Inc. by 59.6% in Q2 2026, now holding 342,883 shares valued at approximately $7.5 million. This increase comes alongside other institutional investments and recent insider stock sales by the CMO and CEO. Despite missing consensus earnings estimates for the quarter, analysts maintain a "Moderate Buy" rating with a consensus price target of $42.36, though some have reduced future earnings forecasts, anticipating a longer path to profitability.
Long term debt to total assets ratio of Syndax Pharmaceuticals Inc – HAM:1T3
This page provides financial data for Syndax Pharmaceuticals Inc (HAM:1T3), specifically focusing on its long-term debt to total assets ratio. It appears to be a financial data portal, offering an overview of the company's financials, although the specific ratio value is not displayed in the provided content. The page also includes navigation for various market data, community features, and tools offered by TradingView.
Bank of America Corp DE Decreases Position in Syndax Pharmaceuticals, Inc. $SNDX
Bank of America Corp DE reduced its stake in Syndax Pharmaceuticals, Inc. by 9.8% in the first quarter, selling over 460,000 shares but still retaining a significant holding worth about $99.3 million. Despite this reduction, other institutional investors like Vanguard, Orbimed Advisors, Qube Research, and Adage Capital increased their positions. Syndax Pharmaceuticals reported a quarterly loss and revenue miss, though analysts maintain a "Moderate Buy" rating with an average price target of $42.36, even as some forecasts for future profitability have been lowered.
Price to sales forward of Syndax Pharmaceuticals Inc – HAM:1T3
This article provides financial data for Syndax Pharmaceuticals Inc, traded on the Hamburg Stock Exchange under the ticker 1T3. It specifically references the "Price to sales forward" metric. The page appears to be a financial data portal, showing various market data and financial tools.
Operating expenses (excl. COGS) of Syndax Pharmaceuticals Inc – HAM:1T3
This page provides financial data, specifically operating expenses (excluding COGS), for Syndax Pharmaceuticals Inc, trading under the symbol 1T3 on the Hamburg Stock Exchange. The content appears to be a financial data snippet from TradingView, indicating that specific figures are available for different periods.
Net margin % of Syndax Pharmaceuticals Inc – HAM:1T3
The article focuses on the net margin percentage of Syndax Pharmaceuticals Inc, traded under the HAM:1T3 symbol on the Hamburg Stock Exchange. It appears to be a stub or a financial data page from TradingView, indicating that the market was closed with no trades at the time of access. The primary content is the title itself, with the rest being navigational and footer elements of the TradingView platform.
Earnings Update: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Just Reported And Analysts Are Trimming Their Forecasts
Syndax Pharmaceuticals (NASDAQ:SNDX) recently reported its latest quarterly results, missing revenue predictions by 8.2% and reporting larger-than-expected statutory losses. Following these results, analysts have trimmed their 2026 revenue forecasts and increased their loss per share expectations, although the consensus price target remains unchanged. Despite the near-term concerns, the company is still projected to grow revenue significantly faster than the industry over the next few years.
State Street Corporation (SNDX) discloses 5.66M-share, 6.4% holding in Syndax
State Street Corporation has reported a significant ownership stake in Syndax Pharmaceuticals Inc., holding 5,658,465 shares of common stock, which represents 6.4% of the class as of June 30, 2026. The filing, a SCHEDULE 13G, indicates that State Street exercises shared voting power over 5,408,786 shares and shared dispositive power over all 5,658,465 shares through various investment management subsidiaries, without any sole voting or dispositive power. This disclosure highlights the beneficial ownership structure by State Street across its affiliated entities.
Earnings Update: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Just Reported And Analysts Are Trimming Their Forecasts
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) recently reported its quarterly earnings, with revenues missing analyst predictions and a larger-than-forecast statutory loss per share. Following these results, analysts have trimmed their revenue forecasts for 2026 and expect an increase in per-share losses, though the consensus price target remains unchanged. Despite the near-term negative adjustments, the company is still expected to grow faster than its industry in terms of revenue.
Earnings Update: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Just Reported And Analysts Are Trimming Their Forecasts
Syndax Pharmaceuticals (NASDAQ:SNDX) recently reported its quarterly earnings, with revenues missing analyst predictions and the company reporting a larger-than-expected statutory loss. Following these results, analysts have downgraded revenue forecasts for 2026 and increased expected per-share losses, although the consensus price target remains largely unchanged. Despite the near-term concerns, Syndax Pharmaceuticals is still anticipated to grow significantly faster than its industry, with projected annualized revenue growth of 59% through 2026.
Five New Syndax Employees Receive Stock Options With 4-Year Vesting
Syndax Pharmaceuticals announced it granted inducement stock option awards for up to 59,250 shares to five new employees on August 1, 2026, under its 2023 Inducement Plan. These options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the subsequent 36 months, conditional on continued employment. The company, a commercial-stage biopharmaceutical firm, is focused on advancing cancer therapies, including its FDA-approved drugs Revuforj and Niktimvo.
Syndax Pharmaceuticals (SNDX) Stock Climbs On Revenue Strength As Losses Persist
Syndax Pharmaceuticals (SNDX) saw its stock climb 4.4% following Q2 earnings that showed significant revenue growth, with sales reaching US$72.8 million for the quarter. While the company's Q2 net loss narrowed to US$49.36 million and management reiterated a funded balance sheet for late-stage programs, it still faces substantial losses exceeding US$200 million annually. The bull case relies on continued growth and expanded use of its key drugs, Revuforj and Niktimvo, while bears remain concerned about product concentration and high R&D spending.
Syndax Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $38.27, Implies 101% Upside
Analyst estimates for Syndax Pharmaceuticals, Inc. (SNDX) show a revised average 12-month price target of $38.27, down from $39.45, with a range between $26 and $57. This new target suggests a potential upside of approximately 101% from its Aug. 4 closing price. The consensus rating from 12 analysts remains a "Buy."
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down on Disappointing Earnings
Syndax Pharmaceuticals (NASDAQ:SNDX) shares gapped down following a disappointing earnings announcement, missing EPS and revenue estimates despite significant year-over-year revenue growth. Analyst sentiment remains largely positive with a "Moderate Buy" rating, though some price targets were adjusted. Insider selling occurred, but institutional investors like AQR Capital Management increased their positions.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals announced inducement awards for five new employees to purchase up to 59,250 shares of common stock under its 2023 Inducement Plan. The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months, subject to continued employment. Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on innovative cancer therapies, including its FDA-approved drugs Revuforj® and Niktimvo™.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals announced inducement grants to five new employees on August 1, 2026, to purchase up to 59,250 shares of common stock under the company's 2023 Inducement Plan. These stock options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the next 36 months, contingent on continued employment. Syndax is a commercial-stage biopharmaceutical company focused on innovative cancer therapies, including its FDA-approved drugs Revuforj® and Niktimvo™.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals announced inducement awards granted to five new employees on August 1, 2026, enabling them to purchase up to 59,250 shares of common stock under the Company's 2023 Inducement Plan. These stock options will vest over four years, with a 25% initial vesting on the one-year anniversary, followed by monthly vesting over the subsequent 36 months, contingent on continued employment. Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on innovative cancer therapies, including its FDA-approved drugs Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr).
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals announced inducement awards for five new employees to purchase up to 59,250 shares of common stock under its 2023 Inducement Plan. These stock options will vest over four years, with a quarter vesting on the one-year anniversary and the remainder monthly thereafter, contingent on continued employment. Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on innovative cancer therapies.
Syndax Pharmaceuticals stock price target lowered to $26 by BofA
BofA Securities has lowered its price target for Syndax Pharmaceuticals (NASDAQ:SNDX) to $26 from $29, while maintaining a Buy rating. This adjustment follows a disappointing second-quarter report where the company missed both revenue and earnings expectations, with Revuforj sales falling below estimates. Despite these setbacks and concerns about the menin class of drugs, BofA remains positive, viewing any stock weakness as an entry point due to the long-term opportunity and the stock's perceived undervaluation by InvestingPro data.
Sei Investments Co. Grows Stake in Syndax Pharmaceuticals, Inc. $SNDX
Sei Investments Co. increased its stake in Syndax Pharmaceuticals, Inc. by 36.3% during the first quarter, now owning 217,600 shares valued at approximately $5.1 million. Despite a recent quarterly loss and missing revenue estimates, analyst sentiment for Syndax Pharmaceuticals remains largely positive, with a "Moderate Buy" consensus and an average price target of $42.55. However, company insiders have sold over 105,000 shares worth about $2.1 million in the last 90 days.
Surging Revenue And Narrower Losses Might Change The Case For Investing In Syndax Pharmaceuticals (SNDX)
Syndax Pharmaceuticals (SNDX) reported strong Q2 2026 results with surging revenue of US$72.79 million and narrowed net losses. The company more than doubled revenue in the first half of 2026, reaching US$137.65 million, indicating improved operating efficiency. This performance supports the investment narrative around its key drugs, Revuforj and Niktimvo, although regulatory and commercial progress for these therapies remains a central short-term catalyst.
Syndax Pharmaceuticals Q2 2026 Earnings Call Transcript
Syndax Pharmaceuticals reported strong commercial growth in Q2 2026, with combined revenue from Revuforj and Niktimvo reaching $115 million. Revuforj sales increased 91% year-over-year, driven by increased treatment duration, while Niktimvo grew 67% year-over-year, expanding its market share in chronic GVHD. The company also highlighted significant pipeline progress with new assets and upcoming data readouts that could unlock multi-billion dollar opportunities, affirming its financial stability and path to profitability.
Syndax Pharmaceuticals Inc (SNDX) (Q2 2026) Earnings Call Highlights: Revenue Surges 92% as ...
Syndax Pharmaceuticals (SNDX) reported a 92% year-over-year revenue surge to $72.8 million in Q2 2026, driven by strong sales of Revuforjo and Niktimvo. Despite some fluctuations in new patient starts for Revuforjo and flattening sequential growth for Niktimvo, the company maintains a robust cash position of $575 million and anticipates multiple pipeline catalysts. Syndax projects peak Revuforjo revenue of $2 billion in the US alone, supported by increasing treatment duration and market penetration.
Syndax Pharmaceuticals earnings missed by $0.07, revenue fell short of estimates
Syndax Pharmaceuticals (NASDAQ: SNDX) reported its second-quarter earnings, missing analyst estimates for EPS by $0.07 with a reported $-0.55 per share, and falling short on revenue with $73M against an estimated $79.8M. The company's stock price has shown a significant increase over the past year, up 51.79%, despite a recent 3-month decline of 11.21%. InvestingPro assesses Syndax Pharmaceuticals' financial health as "fair performance."
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals announced that on August 1, 2026, it granted inducement awards to five new employees, allowing them to purchase up to 59,250 shares of common stock. These stock options will vest over four years, with a quarter vesting on the first anniversary and the remainder vesting monthly thereafter, contingent on continued employment. Syndax is a commercial-stage biopharmaceutical company focused on innovative cancer therapies, including its FDA-approved drugs Revuforj® and Niktimvo™.
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates
Syndax Pharmaceuticals (SNDX) reported a Q2 loss of $0.55 per share, missing the Zacks Consensus Estimate of a $0.45 loss, and revenues of $72.79 million, falling short of estimates by 11.16%. Despite the recent underperformance, the company holds a Zacks Rank #2 (Buy), indicating expected market outperformance. Investors are now awaiting management's commentary on the earnings call and future estimate revisions.
SNDX: Q2 2026 revenue jumped 92% YoY as losses narrowed and pipeline assets advanced
Syndax Pharmaceuticals (SNDX) reported a significant 92% year-over-year revenue increase in Q2 2026, driven by strong sales of Revuforj and Niktimvo. The company also saw a narrowing net loss and expanded its pipeline with two new assets. SNDX maintains robust liquidity to support its ongoing research and development and commercialization efforts.
Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update
Syndax Pharmaceuticals reported strong financial results for Q2 2026, with total revenue of $73 million, a 92% year-over-year increase, driven by significant growth in both Revuforj and Niktimvo net revenues. The company also expanded its pipeline with two new assets and anticipates topline data from multiple Phase 2 trials later in 2026, positioning itself for continued growth and potential profitability.
Precision Trading with Syndax Pharmaceuticals Inc. (SNDX) Risk Zones
This article from Stock Traders Daily provides a detailed analysis of Syndax Pharmaceuticals Inc. (SNDX), highlighting weak near and mid-term sentiment but a strong long-term outlook. It presents AI-generated institutional trading strategies, including position trading, momentum breakout, and risk hedging, tailored for different risk profiles. The analysis also includes multi-timeframe signal analysis with support and resistance levels for SNDX.
Syndax Pharmaceuticals Inc (SNDX) Financial Health: Profitability & Balance Sheet Analysis
Syndax Pharmaceuticals Inc (SNDX) has a financial score of 8.24, placing it 52nd out of 385 companies in the Biotechnology & Medical Research industry, indicating a weak financial status but high operating efficiency. The company's latest quarterly revenue surged by 223.64% year-over-year to $64.86M, and its net profit increased by 49.71% year-over-year. Despite several financial metrics not being disclosed, the analysis highlights significant growth in revenue and profit.
Syndax Pharmaceuticals Inc (SNDX) Institutional Confidence
Syndax Pharmaceuticals Inc (SNDX) currently has an institutional shareholding score of 10.00, placing it first among 385 companies in the Biotechnology & Medical Research industry. The total institutional shareholding proportion has increased by 3.63% quarter-over-quarter, reaching 123.04%. Steven Cohen is the largest institutional shareholder, holding 2.37 million shares.
Bank of New York Mellon Corp Decreases Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX
Bank of New York Mellon Corp reduced its stake in Syndax Pharmaceuticals Inc. by 8.2% in the first quarter, selling over 89,000 shares but still retaining more than 1 million shares valued at $23.5 million. Despite insider selling, analysts maintain a "Moderate Buy" rating with an average price target of $42.55. Syndax Pharmaceuticals reported a narrower-than-expected quarterly loss and significant revenue growth, though its stock recently declined 4.3%.
Syndax Pharmaceuticals, Inc. $SNDX is Eversept Partners LP's 6th Largest Position
Eversept Partners LP reduced its stake in Syndax Pharmaceuticals (NASDAQ:SNDX) by 12.9% in the first quarter, yet it remains their 6th largest position, valued at approximately $67.4 million. Despite insider selling, analyst sentiment is a "Moderate Buy" with an average price target of $42.55. The company's first-quarter revenue increased significantly by 224.3% year-over-year, and it reported a smaller-than-expected loss per share.
Syndax will give a cancer-therapy business update Aug. 4
Syndax Pharmaceuticals (Nasdaq: SNDX) announced it will report its second quarter 2026 financial results and provide a business update on Tuesday, August 4, 2026. The company's management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the results and update, accessible via their website. Following this news, SNDX stock declined by 5.17%.
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
Syndax Pharmaceuticals will announce its second quarter 2026 financial results and provide a business update on Tuesday, August 4, 2026. The company will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the results. A replay of the event will be available on their website for 90 days following the call.
Syndax Pharmaceuticals, Inc. Podcast | SNDX Podcasts & Related Content
This article provides an overview of Syndax Pharmaceuticals, Inc. (SNDX), including its current stock price, market data, and related content categories such as news, earnings calls, financial information, and podcasts. It highlights the company's stock performance for the day and key financial metrics, while also providing a disclaimer about the informational nature of the data.
Syndax Pharmaceuticals Inc (SNDX) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Syndax Pharmaceuticals Inc (SNDX), noting its current valuation score of 7.45 within the Biotechnology & Medical Research industry. It details the company's P/E ratio, which is -7.45, and mentions that P/B, P/S, and P/CF data have not yet been disclosed. The article highlights that the P/E ratio is significantly below its recent high and above its recent low.
Orbimed Advisors LLC Invests $22.48 Million in Syndax Pharmaceuticals, Inc. $SNDX
Orbimed Advisors LLC has made a new investment of $22.48 million in Syndax Pharmaceuticals, acquiring 962,300 shares, representing 1.09% of the company. Despite insider selling, analysts maintain a "Moderate Buy" rating with a positive price target. Syndax Pharmaceuticals reported a smaller-than-expected quarterly loss and significant revenue growth.
SNDX|Syndax Pharmaceuticals Inc|Price:20.810|Chg%:-0.400
Syndax Pharmaceuticals Inc. (SNDX) closed at $20.810, down 1.89%. The company is a commercial-stage biopharmaceutical firm focused on developing cancer therapies, including Revuforj for acute leukemias and solid tumors, and Niktimvo for chronic graft-versus-host disease and idiopathic pulmonary fibrosis. Key executives and shareholdings are provided, along with details on institutional ownership.
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Rating of "Moderate Buy" by Brokerages
Syndax Pharmaceuticals (NASDAQ:SNDX) has received an average rating of "Moderate Buy" from thirteen brokerages, with an average 1-year price target of $42.55. Despite recent analyst upgrades and reaffirmed ratings, the stock was down 1.9% at $20.81, and quarterly revenue missed expectations, although EPS beat estimates. Insider selling has also been noted in recent months.
SNDX|Syndax Pharmaceuticals Inc|Price:20.810|Chg%:-0.400
Syndax Pharmaceuticals Inc (SNDX) is trading at $20.81, down 1.89%, with a market capitalization of $1.82 billion. The company, focused on cancer therapies like Revuforj and Niktimvo, is rated as a "Buy" by analysts with a target price of $40.545, indicating a high upside potential. Despite an average stock market performance recently, its fundamentals are stable, and growth potential is considered high, though institutional selling has been noted alongside high institutional ownership.
Granahan Investment Management LLC Cuts Stock Position in Syndax Pharmaceuticals, Inc. $SNDX
Granahan Investment Management LLC reduced its stake in Syndax Pharmaceuticals (NASDAQ:SNDX) by 16.5% during the first quarter, selling 60,472 shares and retaining 306,321 shares valued at $7.16 million. This reduction comes amid other institutional investors making varied changes to their positions and recent insider selling by the company's CMO and CEO. Syndax Pharmaceuticals recently reported a smaller-than-expected loss of ($0.48) per share and a significant 224.3% year-over-year revenue increase to $64.86 million.
Syndax Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:SNDX
This article provides a revenue breakdown for Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX). The company generated $172.35 million USD last year, primarily from its Pharmaceuticals segment and the United States market. This marks a significant increase from the previous year's revenue of $23.68 million USD.
Price to sales forward of Syndax Pharmaceuticals Inc – SWB:1T3
This article provides a brief financial update on Syndax Pharmaceuticals Inc (SWB:1T3) from the Stuttgart Stock Exchange, specifically focusing on its "Price to sales forward" metric. The content indicates that the market is closed, with no trades, and offers a link to view the financial data.
